ABBV - AbbVie Inc.
Close
176.74
-0.375 -0.212%
Share volume: 4,734,094
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.38%
PREVIOUS CLOSE
CHG
CHG%
$177.12
1.57
0.01%
Fundamental analysis
37%
Profitability
29%
Dept financing
33%
Liquidity
11%
Performance
52%
Performance
5 Days
0.90%
1 Month
2.98%
3 Months
-9.67%
6 Months
5.18%
1 Year
9.45%
2 Year
15.64%
Key data
Stock price
$176.74
DAY RANGE
$174.34 - $177.98
52 WEEK RANGE
$156.35 - $207.32
52 WEEK CHANGE
$9.45
DIVIDEND
$1.55
EX-DIVIDEND DATE
07/15/2024
NEXT EARNINGS DATE
N/A
Company detail
CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: 2013
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: 2013
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.
Recent news